ESMO Asia 2025: key results and trends

What the 602 abstracts at ESMO Asia 2025 reported, drug by drug: the readouts that stood out and the targets and modalities that dominated.

abstracts
602
drug-linked abstracts
301
companies
90
from Phase 3 studies
42

Drug-linked abstracts by phase

  • Phase 1 21
  • Phase 1/2 16
  • Phase 2 73
  • Phase 2/3 2
  • Phase 3 42
  • Phase 4 2

Key results

Quotes are taken verbatim from each abstract's results; selection is automated. Report an issue

  1. Phase 3Metastatic colon cancer (mCRC)Pfizer

    encorafenib

    199MO First-line (1L) encorafenib + cetuximab + mFOLFOX6 in East Asian patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC): Results from the phase III BREAKWATER study

    Median PFS by BICR was 14.0 vs 7.1 mo, and median OS was not estimable (NE) vs 13.7 mo for EC+mFOLFOX6 vs control.

    Read the abstract (opens in a new tab)
  2. Phase 3Cervical cancer (mCC)

    tisotumab vedotin

    609MO Tisotumab vedotin vs investigator’s choice of chemotherapy as second- or third-line (2L/3L) treatment for Chinese patients (pts) with recurrent or metastatic cervical cancer (r/mCC) in innovaTV 301

    Median (95% CI) OS was not reached (9.7 months–not estimable) with TV vs 10.7 months (6.0-not estimable) with chemotherapy (HR 0.55; 95% CI 0.27–1.15).

    Read the abstract (opens in a new tab)
  3. Phase 3Gastric adenocarcinoma

    retlirafusp alfa

    298P SHR-1701 plus CAPOX in patients with advanced gastric or gastroesophageal junction adenocarcinoma and PD-L1 combined positive score ≥1: A post-hoc analysis of a phase III study

    Median OS was 16.7 months (95% CI, 14.4-18.5) in the SHR-1701 group versus 10.3 months (95% CI, 9.3-12.1) in the placebo group (HR=0.56; 95% CI, 0.45-0.71).

    Read the abstract (opens in a new tab)
  4. Phase 3Non-small cell lung cancer (NSCLC)BeyondSpring

    plinabulin

    979MO Plinabulin/docetaxel vs. docetaxel in 2L/3L EGFRwt NSCLC after platinum regimens (DUBLIN-3): Asian subgroup analysis

    At 24-months (Mo) follow-up after database lock (DB), the survival benefit persisted with mOS favoring DP (10.8 vs. 8.8 Mo, HR=0.80, p=0.0300), and more pronounced in non-squamous (NSQ) pts (11.4 vs. 8.4 Mo, HR=0.69, p=0.0064).

    Read the abstract (opens in a new tab)
  5. Phase 3Small cell lung cancer (SCLC)

    lurbinectedin

    980MO Lurbinectedin (lurbi) + atezolizumab (atezo) as first-line (1L) maintenance treatment (tx) in patients (pts) with extensive-stage small-cell lung cancer (ES-SCLC): IMforte Asia subgroup results

    At data cutoff (29 Jul 2024), IRF-PFS was improved with lurbi + atezo vs atezo (median, 6.3 vs 1.8 mo; unstratified HR, 0.48; 95% CI: 0.27, 0.87), as was OS (median, 16.5 vs 12.2 mo; unstratified HR, 0.81; 95% CI: 0.37, 1.75).

    Read the abstract (opens in a new tab)
  6. Phase 3Well-differentiated thyroid cancer (WDTC)Novartis

    dabrafenib + trametinib

    1165P Safety profile of dabrafenib plus trametinib (D+T) in previously treated Chinese Mainland subgroup (CMS) population with radioactive iodine (RAI)–refractory BRAF V600E mutation–positive differentiated thyroid cancer (DTC)

    The incidence of grade ≥3 AEs was higher in the D+T (52.8%) than the PBO arm (21.7%).

    Read the abstract (opens in a new tab)
  7. Phase 2/3Pancreatic cancer (PDAC)HUTCHMED

    surufatinib

    375P Surufatinib (S) in combination with camrelizumab (C), nab-paclitaxel and gemcitabine (AG) as the first-line treatment in metastatic pancreatic cancer: Results from phase II part of a randomized, open-label, active-controlled, phase II/III study

    With the median PFS follow-up duration of 8.15 months (m), S+C+AG demonstrated superior median PFS vs AG (7.20m vs 5.52m, stratified hazard ratio [HR] 0.499, log-rank P = 0.0407).

    Read the abstract (opens in a new tab)
  8. Phase 2Gastric adenocarcinoma

    adebrelimab

    277MO Efficacy and safety of adebrelimab combined with S-1 plus oxaliplatin in neoadjuvant therapy for locally advanced gastric adenocarcinoma

    The ASO group achieved significantly higher pCR rates compared to PSO group (25.45% vs 1.82%, p<0.0001), with marked tumor downstaging (ypT0: 25.45% vs 1.82%; ypN0: 65.45% vs 21.82%, both p<0.0001).

    Read the abstract (opens in a new tab)
  9. Phase 2Metastatic colon cancer (mCRC)

    fruquintinib

    205P Fruquintinib combined with TAS-102 with or without SBRT as third- or later-line treatment in metastatic colorectal cancer : Preliminary results from a prospective phase II trial

    ORR was 36.4% (4/11) in FTS vs 12% (3/25) in FT,and mPFS was not reached in FTS vs 8.58 months (95% CI: 4.57–9.00) in FT.

    Read the abstract (opens in a new tab)
  10. Phase 1Non-small cell lung cancer (NSCLC)Boehringer Ingelheim

    zongertinib

    986P Zongertinib in HER2-mutant advanced NSCLC: Impact of therapy line on efficacy

    In patients who received 3L zongertinib, the confirmed ORR was 75.0% (46.8–91.1)

    Read the abstract (opens in a new tab)

What the abstracts covered

Share of the 301 drug-linked abstracts, by the target, modality, disease and company of each drug. An abstract can count in more than one row, so a list can add up to more than 100%.

  • Antibody-drug conjugates9%28 drug-linked abstracts
  • Bispecific antibodies5%14 drug-linked abstracts

Top targets

  1. PDCD15518%
  2. EGFR3110%
  3. ERBB2269%
  4. CD274238%
  5. MET145%
  6. VEGFR2145%
  7. VEGFR4145%
  8. TUBB134%
  9. VEGFR-1134%
  10. RET124%

Top modalities

  1. Small molecules15351%
  2. Monoclonal antibodies9030%
  3. Antibody-drug conjugates289%
  4. Bispecific antibodies145%
  5. Non-antibody therapeutic proteins72%
  6. Natural-product mixtures and botanicals62%
  7. Peptides52%
  8. Vaccines31%

Top diseases

  1. Non-small cell lung cancer (NSCLC)7826%
  2. Breast cancer3411%
  3. Gastric cancer (GC)186%
  4. Hepatocellular carcinoma (HCC)155%
  5. Head and neck squamous cell carcinoma (HNSCC)134%
  6. Gastric adenocarcinoma93%
  7. Gastroesophageal junction adenocarcinoma93%
  8. Prostate cancer (PCa)93%
  9. Colorectal cancer (CRC)83%
  10. Pancreatic cancer (PC)83%

Most active companies

  1. AstraZeneca279%
  2. Bristol Myers Squibb186%
  3. Merck165%
  4. Genentech103%
  5. Pfizer103%
  6. HUTCHMED93%
  7. Jiangsu HengRui Medicine Co., Ltd.93%
  8. Eisai83%
  9. Henlius83%
  10. BeiGene72%

Explore every ESMO Asia 2025 result in Gosset

All 301 drug-linked abstracts, joined to each drug’s trials, targets, developers and deals, with a source behind every line.

This page shows a sample of results. Gosset has the abstracts from this meeting and 100+ others; reach out for full access.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call